RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Deepa Bedi to Antineoplastic Agents

This is a "connection" page, showing publications Deepa Bedi has written about Antineoplastic Agents.
Connection Strength

0.403
  1. Bedi D, Gillespie JW, Petrenko VA. Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines. Protein Eng Des Sel. 2014 Jul; 27(7):235-43.
    View in: PubMed
    Score: 0.283
  2. Wang T, D'Souza GG, Bedi D, Fagbohun OA, Potturi LP, Papahadjopoulos-Sternberg B, Petrenko VA, Torchilin VP. Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond). 2010 Jun; 5(4):563-74.
    View in: PubMed
    Score: 0.054
  3. Jayanna PK, Bedi D, Gillespie JW, DeInnocentes P, Wang T, Torchilin VP, Bird RC, Petrenko VA. Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency. Nanomedicine. 2010 Aug; 6(4):538-46.
    View in: PubMed
    Score: 0.052
  4. Wang T, Kulkarni N, Bedi D, D'Souza GG, Papahadjopoulos-Sternberg B, Petrenko VA, Torchilin VP. In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein. J Drug Target. 2011 Sep; 19(8):597-605.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support